Cargando…
Glecaprevir/pibrentasvir for the treatment of chronic hepatitis C: design, development, and place in therapy
Direct-acting antiviral (DAA) therapy has changed the landscape of hepatitis C virus (HCV) management and has changed the focus to the possibility of HCV elimination in the near future. Glecaprevir, an NS3/4A protease inhibitor, and pibrentasvir, an HCV NS5A inhibitor, have addressed many of the exi...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Dove
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6681154/ https://www.ncbi.nlm.nih.gov/pubmed/31534310 http://dx.doi.org/10.2147/DDDT.S172512 |